1
|
Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, Venkataramani K, Steinfeld JS, Han W, Li M, Liu M, Wang Z, Besschetnova A, Patalano S, Mulhearn MJ, Macoska JA, Yuan X, Balk SP, Nelson PS, Plymate SR, Gao S, Siegfried KR, Liu R, Stangis MM, Foxa G, Czernik PJ, Williams BO, Zarringhalam K, Li X, Cai C. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. J Clin Invest 2024:e168649. [PMID: 38687617 DOI: 10.1172/jci168649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024] Open
Abstract
One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and constitutively active AR splice variants, particularly AR-V7. While AR-V7 has been intensively studied, its ability to activate distinct biological functions compared to the full-length AR (AR-FL), and its role in regulating the metastatic progression of castration-resistant PCa (CRPC), remains unclear. Our study found that, under castrated conditions, AR-V7 strongly induced osteoblastic bone lesions, a response not observed with AR-FL overexpression. Through combined ChIP-seq, ATAC-seq, and RNA-seq analyses, we demonstrated that AR-V7 uniquely accesses the androgen-responsive elements in compact chromatin regions, activating a distinct transcription program. This program was highly enriched for genes involved in epithelial-mesenchymal transition and metastasis. Notably, we discovered that SOX9, a critical metastasis driver gene, was a direct target and downstream effector of AR-V7. Its protein expression was dramatically upregulated in AR-V7-induced bone lesions. Moreover, we found that Ser81 phosphorylation enhanced AR-V7's pro-metastasis function by selectively altering its specific transcription program. Blocking this phosphorylation with CDK9 inhibitors impaired the AR-V7-mediated metastasis program. Overall, our study has provided molecular insights into the role of AR splice variants in driving the metastatic progression of CRPC.
Collapse
Affiliation(s)
- Dong Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Maryam Labaf
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Yawei Zhao
- Cell and Cancer Biology, The University of Toledo, Toledo, United States of America
| | - Jude Owiredu
- Cell and Developmental Biology, Weill Cornell Medical College, New York, United States of America
| | - Songqi Zhang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Krishna Patel
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | | | - Jocelyn S Steinfeld
- Biology, University of Massachusetts Boston, Boston, United States of America
| | - Wanting Han
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, United States of America
| | - Muqing Li
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Mingyu Liu
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Zifeng Wang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Anna Besschetnova
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Susan Patalano
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Michaela J Mulhearn
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Jill A Macoska
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Xin Yuan
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States of America
| | - Steven P Balk
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States of America
| | - Peter S Nelson
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, United States of America
| | - Stephen R Plymate
- Medicine, University of Washington, Seattle, United States of America
| | - Shuai Gao
- Cell Biology and Anatomy, New York Medical College, Valhalla, United States of America
| | - Kellee R Siegfried
- Biology, University of Massachusetts Boston, Boston, United States of America
| | - Ruihua Liu
- Cell and Cancer Biology, The University of Toledo, Toledo, United States of America
| | - Mary M Stangis
- Cell and Cancer Biology, The University of Toledo, Toledo, United States of America
| | - Gabrielle Foxa
- Cell Biology, Van Andel Institute Core Technologies and Services, Grand Rapids, United States of America
| | - Piotr J Czernik
- Orthopaedic Surgery, University of Toledo, Toledo, United States of America
| | - Bart O Williams
- Cell Biology, Van Andel Institute Core Technologies and Services, Grand Rapids, United States of America
| | - Kourosh Zarringhalam
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| | - Xiaohong Li
- Cell and Cancer Biology, University of Toledo, Toledo, United States of America
| | - Changmeng Cai
- Center of Personalized Cancer Therapy, University of Massachusetts Boston, Boston, United States of America
| |
Collapse
|
2
|
Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, Besschetnova A, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Vedadi M, Arrowsmith CH, He HH, Cai C. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proc Natl Acad Sci U S A 2023; 120:e2220472120. [PMID: 37549269 PMCID: PMC10438836 DOI: 10.1073/pnas.2220472120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 06/29/2023] [Indexed: 08/09/2023] Open
Abstract
Dysregulation of histone lysine methyltransferases and demethylases is one of the major mechanisms driving the epigenetic reprogramming of transcriptional networks in castration-resistant prostate cancer (CRPC). In addition to their canonical histone targets, some of these factors can modify critical transcription factors, further impacting oncogenic transcription programs. Our recent report demonstrated that LSD1 can demethylate the lysine 270 of FOXA1 in prostate cancer (PCa) cells, leading to the stabilization of FOXA1 chromatin binding. This process enhances the activities of the androgen receptor and other transcription factors that rely on FOXA1 as a pioneer factor. However, the identity of the methyltransferase responsible for FOXA1 methylation and negative regulation of the FOXA1-LSD1 oncogenic axis remains unknown. SETD7 was initially identified as a transcriptional activator through its methylation of histone 3 lysine 4, but its function as a methyltransferase on nonhistone substrates remains poorly understood, particularly in the context of PCa progression. In this study, we reveal that SETD7 primarily acts as a transcriptional repressor in CRPC cells by functioning as the major methyltransferase targeting FOXA1-K270. This methylation disrupts FOXA1-mediated transcription. Consistent with its molecular function, we found that SETD7 confers tumor suppressor activity in PCa cells. Moreover, loss of SETD7 expression is significantly associated with PCa progression and tumor aggressiveness. Overall, our study provides mechanistic insights into the tumor-suppressive and transcriptional repression activities of SETD7 in mediating PCa progression and therapy resistance.
Collapse
Affiliation(s)
- Zifeng Wang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Jessica Petricca
- Department of Medical Biophysics, University of Toronto, Toronto, ONM5G1L7, Canada
- Princess Margaret Cancer Center, University Health Network, Toronto, ONM5G1L7, Canada
| | - Mingyu Liu
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Songqi Zhang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Sujun Chen
- Department of Medical Biophysics, University of Toronto, Toronto, ONM5G1L7, Canada
- Princess Margaret Cancer Center, University Health Network, Toronto, ONM5G1L7, Canada
- West China School of Public Health, West China Fourth Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan610041, China
| | - Muqing Li
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Anna Besschetnova
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Susan Patalano
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | | | | | - Jill A. Macoska
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Dong Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| | - Shuai Gao
- Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY10595
- Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY10595
| | - Masoud Vedadi
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ONM5S 1A8, Canada
- Structural Genomics Consortium, University of Toronto, Toronto, ONM5S 1A8, Canada
| | - Cheryl H. Arrowsmith
- Department of Medical Biophysics, University of Toronto, Toronto, ONM5G1L7, Canada
- Princess Margaret Cancer Center, University Health Network, Toronto, ONM5G1L7, Canada
- Structural Genomics Consortium, University of Toronto, Toronto, ONM5S 1A8, Canada
| | - Housheng Hansen He
- Department of Medical Biophysics, University of Toronto, Toronto, ONM5G1L7, Canada
- Princess Margaret Cancer Center, University Health Network, Toronto, ONM5G1L7, Canada
| | - Changmeng Cai
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA02125
- Department of Biology, University of Massachusetts Boston, Boston, MA02125
| |
Collapse
|
3
|
Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, Labaf M, Patalano S, Venkataramani K, Muriph RE, Macoska JA, Siegfried KR, Evans J, Balk SP, Gao S, Han D, Cai C. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression. Cancer Res Commun 2023; 3:1716-1730. [PMID: 37663929 PMCID: PMC10470473 DOI: 10.1158/2767-9764.crc-23-0208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 06/20/2023] [Accepted: 08/04/2023] [Indexed: 09/05/2023]
Abstract
Epigenetic reprogramming, mediated by genomic alterations and dysregulation of histone reader and writer proteins, plays a critical role in driving prostate cancer progression and treatment resistance. However, the specific function and regulation of EHMT1 (also known as GLP) and EHMT2 (also known as G9A), well-known histone 3 lysine 9 methyltransferases, in prostate cancer progression remain poorly understood. Through comprehensive investigations, we discovered that both EHMT1 and EHMT2 proteins have the ability to activate oncogenic transcription programs in prostate cancer cells. Silencing EHMT1/2 or targeting their enzymatic activity with small-molecule inhibitors can markedly decrease prostate cancer cell proliferation and metastasis in vitro and in vivo. In-depth analysis of posttranslational modifications of EHMT1 protein revealed the presence of methylation at lysine 450 and 451 residues in multiple prostate cancer models. Notably, we found that lysine 450 can be demethylated by LSD1. Strikingly, concurrent demethylation of both lysine residues resulted in a rapid and profound expansion of EHMT1's chromatin binding capacity, enabling EHMT1 to reprogram the transcription networks in prostate cancer cells and activate oncogenic signaling pathways. Overall, our studies provide valuable molecular insights into the activity and function of EHMT proteins during prostate cancer progression. Moreover, we propose that the dual-lysine demethylation of EHMT1 acts as a critical molecular switch, triggering the induction of oncogenic transcriptional reprogramming in prostate cancer cells. These findings highlight the potential of targeting EHMT1/2 and their demethylation processes as promising therapeutic strategies for combating prostate cancer progression and overcoming treatment resistance. Significance In this study, we demonstrate that EHMT1 and EHMT2 proteins drive prostate cancer development by transcriptionally activating multiple oncogenic pathways. Mechanistically, the chromatin binding of EHMT1 is significantly expanded through demethylation of both lysine 450 and 451 residues, which can serve as a critical molecular switch to induce oncogenic transcriptional reprogramming in prostate cancer cells.
Collapse
Affiliation(s)
- Anna Besschetnova
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Wanting Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington
| | - Mingyu Liu
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Yanfei Gao
- Department of Orthopedics, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China
| | - Muqing Li
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Zifeng Wang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Maryam Labaf
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Mathematics, University of Massachusetts Boston, Boston, Massachusetts
| | - Susan Patalano
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Kavita Venkataramani
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Rachel E. Muriph
- Department of Chemistry, University of Massachusetts Boston, Boston, Massachusetts
| | - Jill A. Macoska
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Kellee R. Siegfried
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Jason Evans
- Department of Chemistry, University of Massachusetts Boston, Boston, Massachusetts
| | - Steven P. Balk
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
| | - Shuai Gao
- Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York
- Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York
| | - Dong Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| | - Changmeng Cai
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts
- Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
| |
Collapse
|
4
|
Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, Labaf M, Patalano S, Venkataramani K, Muriph R, Macoska J, Siegfried-Harris K, Evans J, Balk S, Gao S, Han D, Cai C. Abstract A021: Lysine methylation in EHMT1/GLP acts as a molecular switch to reprogram transcription networks to drive prostate cancer progression. Cancer Res 2022. [DOI: 10.1158/1538-7445.cancepi22-a021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
Abstract
Background: Prostate Cancer (PCa) progresses to a metastatic form of cancer called Castration-Resistant Prostate Cancer (CRPC) after treatment with androgen deprivation therapies (ADTs). Epigenetic reprogramming through altered expression and activity of histone modifier proteins is one major mechanism of tumor resistance. In particular, histone lysine methyltransferases (KMTs) and demethylases (KDMs) are important epigenetic targets in CRPC. In this study, we have focused on studying the function and regulation of Euchromatic Histone Methyltransferase 1 protein (EHMT1/GLP), which is a well-known H3K9 methyltransferase and functions in repressing gene transcription. EHMT family genes are altered in ~2-3% of primary PCa and ~10% of CRPC (primarily gene amplification) and their expression levels are significantly increased in CRPC, suggesting these proteins may have oncogenic activities in driving CRPC progression. Methods: We conducted an integrated analysis of ChIP-seq and RNA-seq analysis in LNCaP PCa cells to characterize the transcription program of EHMT1. We then performed proteomics analyses in VCaP and LNCaP PCa cells to identify post-translational modifications of EHMT1 and functionally validated the findings by generating loss-of-function mutations. We performed a histone demethylase assay to discover if EHMT1 is a substrate of LSD1 (a member of the KDM family). Moreover, we also assessed the effects of EHMT1 silencing or inhibition (in multiple PCa cell lines) on cell proliferation and metastasis in vitro using cell cycle analysis and transwell migration assay, and tumor growth and metastasis in vivo using mouse subcutaneous injection and zebrafish embryo injection approaches. Results: Our data showed that EHMT1 can transcriptionally activate multiple oncogenic pathways, including E2F and MYC signaling. Proteomic analyses revealed that EHMT1 is methylated in PCa cell lines, with dual-lysine methylation occurring at the K450/K451 sites. The histone demethylase assay showed that methylated K450, but not K451 is a potential substrate of LSD1. By generating the K450R, K451R, and K450/451R mutants, we showed that the K450/451R mutant, but not any single lysine mutants, can greatly expand EHMT1 chromatin binding independent of its H3K9 methyltransferase activity. This mutant also significantly induced EHMT1 oncogenic activity by activating E2F and MYC pathways. Moreover, EHMT1 silencing, or inhibition can significantly suppress tumor growth and metastasis. Conclusion: We have demonstrated that EHMT1 can function to activate oncogenic transcriptional programs in PCa by an H3K9-independent mechanism, possibly mediated through dual-lysine demethylation at K450/451 sites. Our data also suggest that targeting EHMT1 in CRPC may be a potential therapeutic strategy to suppress tumor growth and metastasis.
Citation Format: Anna Besschetnova, Wanting Han, Mingyu Liu, Yanfei Gao, Muqing Li, Zifeng Wang, Maryam Labaf, Susan Patalano, Kavita Venkataramani, Rachel Muriph, Jill Macoska, Kellee Siegfried-Harris, Jason Evans, Steven Balk, Shuai Gao, Dong Han, Changmeng Cai. Lysine methylation in EHMT1/GLP acts as a molecular switch to reprogram transcription networks to drive prostate cancer progression. [abstract]. In: Proceedings of the AACR Special Conference: Cancer Epigenomics; 2022 Oct 6-8; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_2):Abstract nr A021.
Collapse
Affiliation(s)
| | - Wanting Han
- 2Fred Hutchinson Cancer Research Center, Seattle, WA,
| | - Mingyu Liu
- 1University of Massachusetts Boston, Boston, MA,
| | - Yanfei Gao
- 3Chongqing Medical University, Chongqing, China,
| | - Muqing Li
- 1University of Massachusetts Boston, Boston, MA,
| | - Zifeng Wang
- 1University of Massachusetts Boston, Boston, MA,
| | - Maryam Labaf
- 1University of Massachusetts Boston, Boston, MA,
| | | | | | | | - Jill Macoska
- 1University of Massachusetts Boston, Boston, MA,
| | | | - Jason Evans
- 1University of Massachusetts Boston, Boston, MA,
| | - Steven Balk
- 4Beth Israel Deaconess Medical Center, Boston, MA
| | - Shuai Gao
- 1University of Massachusetts Boston, Boston, MA,
| | - Dong Han
- 1University of Massachusetts Boston, Boston, MA,
| | | |
Collapse
|
5
|
Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai C. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Mol Ther 2022; 30:1628-1644. [PMID: 35121110 PMCID: PMC9077383 DOI: 10.1016/j.ymthe.2022.01.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 12/15/2021] [Accepted: 01/28/2022] [Indexed: 10/19/2022] Open
Abstract
The androgen receptor (AR) plays a pivotal role in driving prostate cancer (PCa) development. However, when stimulated by high levels of androgens, AR can also function as a tumor suppressor in PCa cells. While the high-dose testosterone (high-T) treatment is currently being tested in clinical trials of castration-resistant prostate cancer (CRPC), there is still a pressing need to fully understand the underlying mechanism and thus develop treatment strategies to exploit this tumor-suppressive activity of AR. In this study, we demonstrate that retinoblastoma (Rb) family proteins play a central role in maintaining the global chromatin binding and transcriptional repression program of AR and that Rb inactivation desensitizes CRPC to the high-dose testosterone treatment in vitro and in vivo. Using a series of patient-derived xenograft (PDX) CRPC models, we further show that the efficacy of high-T treatment can be fully exploited by a CDK4/6 inhibitor, which strengthens the chromatin binding of the Rb-E2F repressor complex by blocking the hyperphosphorylation of Rb proteins. Overall, our study provides strong mechanistic and preclinical evidence on further developing clinical trials to combine high-T with CDK4/6 inhibitors in treating CRPC.
Collapse
|
6
|
Han W, Liu M, Han D, Li M, Toure AA, Wang Z, Besschetnova A, Patalano S, Macoska JA, Gao S, He HH, Cai C. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene 2022; 41:852-864. [PMID: 34975152 PMCID: PMC8818029 DOI: 10.1038/s41388-021-02135-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 11/12/2021] [Accepted: 11/23/2021] [Indexed: 12/12/2022]
Abstract
Genomic loss of RB1 is a common alteration in castration-resistant prostate cancer (CRPC) and is associated with poor patient outcomes. RB1 loss is also a critical event that promotes the neuroendocrine transdifferentiation of prostate cancer (PCa) induced by the androgen receptor (AR) signaling inhibition (ARSi). The loss of Rb protein disrupts the Rb-E2F repressor complex and thus hyperactivates E2F transcription activators. While the impact of Rb inactivation on PCa progression and linage plasticity has been previously studied, there is a pressing need to fully understand underlying mechanisms and identify vulnerabilities that can be therapeutically targeted in Rb-deficient CRPC. Using an integrated cistromic and transcriptomic analysis, we have characterized Rb activities in multiple CRPC models by identifying Rb directly regulated genes and revealed that Rb has distinct binding sites and targets in CRPC with different genomic backgrounds. Significantly, we show that E2F1 chromatin binding and transcription activity in Rb-deficient CRPC are highly dependent on LSD1/KDM1A, and that Rb inactivation sensitizes CRPC tumor to the LSD1 inhibitor treatment. These results provide new molecular insights into Rb activity in PCa progression and suggest that targeting LSD1 activity with small molecule inhibitors may be a potential treatment strategy to treat Rb-deficient CRPC.
Collapse
Affiliation(s)
- Wanting Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Mingyu Liu
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Dong Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Muqing Li
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Anthia A Toure
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Zifeng Wang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Anna Besschetnova
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Susan Patalano
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Jill A Macoska
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Shuai Gao
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA
| | - Housheng Hansen He
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.,Princess Margaret Cancer Center, University Health Network, Toronto, ON, M5G1L7, Canada
| | - Changmeng Cai
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA. .,Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA.
| |
Collapse
|
7
|
Besschetnova A, Han W, Liu M, Han D, Gao S, Cai C. Abstract 2152: EHMT1 activity to repress neuroendocrine differentiation of prostate cancer is mediated by dual lysine-methylation. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-2152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Lysine methylation is an important post-translational regulation on histones, but its molecular functions on non-histone proteins remain largely unknown. In a pilot study, we identified novel lysine methylations at non-histone proteins in prostate cancer (PCa) cells through an affinity pull-down assay. EHMT1/GLP, containing monomethylated K450 and K451, was one of these proteins, and it was known to repress transcription through methylating histone 3 lysine 9 (H3K9). EHMT1 and EHMT2/G9a are members of the REST (NRSF) repressor complex, that includes LSD1/CoREST/HDACs and represses neuronal genes in non-neuronal cells. Loss of function for this complex has been indicated as a mechanism to drive neuroendocrine (NE) transition of PCa. We hypothesize that the K450/451 methylations may inhibit the activity of EHMT1 and that LSD1 and other lysine demethylase(s) may sequentially demethylate these lysines and thus induce EHMT1 activity to silence the expression of NE related genes.
Methods: LNCaP stable cell lines overexpressing doxycycline-regulated V5-tagged EHMT1-WT, K450R, K451R, and K450/451R were generated. We performed ChIP-seq analyses of V5 and H3K9me2, and RNA-seq analyses in all four cell lines treated with/out doxycycline. We also conducted in vitro demethylation assays to examine whether LSD1 directly demethylates EHMT1. Moreover, we performed co-immunoprecipitation assays to determine the effect of LSD1 inhibition on the interaction of LSD1 with EHMT1. Neuronal target gene expression was examined through ChIP and mRNA analysis.
Results: Using mass-spectrometry analysis, we confirmed K450 and K451 methylations of EHMT1 in LNCaP PCa cell line. The demethylation assays indicated that methylated K450 but not K451 is a potential substrate of LSD1. Moreover, LSD1 interacts with K450/451R mutant but not EHMT1-WT. Importantly, only K450/451R mutant had a significant increase of chromatin binding in V5 and elevated levels of H3K9me2 compared to the weak chromatin binding seen in WT, K450R and K451R. Analyses in RNA-Seq revealed that the K450/K451R mutant repressed genes enriched for neuronal pathways, which was not seen in WT, K450R or K451R.
Conclusions: Our studies suggest that both K450 and K451 of EHMT1 are methylated in PCa cells. K450-methylation of EHMT1 can be specifically demethylated by LSD1, but this alone is not sufficient to induce the chromatin recruitment of EHMT1. However, demethylation at both K450/K451 can dramatically increase the chromatin binding of EHMT1, which subsequently represses neuronal pathways. This mechanism may be particularly important for maintaining the cell lineage of adenocarcinoma of PCa and loss of this demethylation might lead to the emergence of NE-like PCa.
Citation Format: Anna Besschetnova, Wanting Han, Mingyu Liu, Dong Han, Shuai Gao, Changmeng Cai. EHMT1 activity to repress neuroendocrine differentiation of prostate cancer is mediated by dual lysine-methylation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2152.
Collapse
Affiliation(s)
| | - Wanting Han
- University of Massachusetts Boston, Boston, MA
| | - Mingyu Liu
- University of Massachusetts Boston, Boston, MA
| | - Dong Han
- University of Massachusetts Boston, Boston, MA
| | - Shuai Gao
- University of Massachusetts Boston, Boston, MA
| | | |
Collapse
|
8
|
Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, Patalano S, Macoska JA, Corey E, Chen S, Balk SP, He HH, Cai C. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet 2020; 52:1011-1017. [PMID: 32868907 PMCID: PMC7541538 DOI: 10.1038/s41588-020-0681-7] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Accepted: 07/24/2020] [Indexed: 11/09/2022]
Abstract
FOXA1 functions as a pioneer transcription factor by facilitating the access to chromatin for steroid hormone receptors, such as androgen receptor and estrogen receptor1-4, but mechanisms regulating its binding to chromatin remain elusive. LSD1 (KDM1A) acts as a transcriptional repressor by demethylating mono/dimethylated histone H3 lysine 4 (H3K4me1/2)5,6, but also acts as a steroid hormone receptor coactivator through mechanisms that are unclear. Here we show, in prostate cancer cells, that LSD1 associates with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding. Mechanistically, we demonstrate that LSD1 positively regulates FOXA1 binding by demethylating lysine 270, adjacent to the wing2 region of the FOXA1 DNA-binding domain. Acting through FOXA1, LSD1 inhibition broadly disrupted androgen-receptor binding and its transcriptional output, and dramatically decreased prostate cancer growth alone and in synergy with androgen-receptor antagonist treatment in vivo. These mechanistic insights suggest new therapeutic strategies in steroid-driven cancers.
Collapse
Affiliation(s)
- Shuai Gao
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Sujun Chen
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.,Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada
| | - Dong Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Zifeng Wang
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Muqing Li
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Wanting Han
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Anna Besschetnova
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Mingyu Liu
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Feng Zhou
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.,Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - David Barrett
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - My Phu Luong
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Jude Owiredu
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.,Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Yi Liang
- Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada
| | - Musaddeque Ahmed
- Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada
| | - Jessica Petricca
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.,Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada
| | - Susan Patalano
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Jill A Macoska
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA
| | - Eva Corey
- Department of Urology, University of Washington, Seattle, WA, USA
| | - Sen Chen
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Steven P Balk
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
| | - Housheng Hansen He
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. .,Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.
| | - Changmeng Cai
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
| |
Collapse
|